TrialThe Lancet. Infectious diseases2021

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Kelly E Dooley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.